Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Traws Pharma ( (TRAW) ) has provided an update.
On May 15, 2025, Traws Pharma announced its financial results for the quarter ended March 31, 2025, highlighting progress in its investigational programs for tivoxavir marboxil and ratutrelvir, targeting bird flu/seasonal flu and COVID-19 respectively. The company submitted briefing materials to the FDA for potential accelerated approval of tivoxavir marboxil and plans to seek regulatory input for ratutrelvir. Financially, Traws Pharma reported a net income of $21.5 million, driven by changes in warrant liability, with cash reserves expected to support operations into Q1 2026. The company’s efforts to advance its antiviral programs could significantly impact its market positioning and offer substantial opportunities in the multi-billion dollar U.S. market.
The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting critical threats to human health from respiratory viral diseases. The company is primarily engaged in the development of investigational oral small molecule antivirals for bird flu, seasonal flu, and COVID-19.
Average Trading Volume: 94,351
Technical Sentiment Signal: Sell
Current Market Cap: $6.51M
For an in-depth examination of TRAW stock, go to TipRanks’ Stock Analysis page.